Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
In the therapeutic schemes of the hormone-dependent gynecologic cancers, the combined administration of tamoxifen and medroxyprogesterone, generally, scores better results. The highly hormone-dependent tumors (ER+, PgR+) respond very well to a combined, simultaneous treatment. The strictly hormone-dependent (ER+, PgR-) and the potentially hormone-dependent (ER-, PgR-) tumors seem to be most efficiently treated by means of a combined, successive scheme.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D014592:Uterine Hemorrhage / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000188:drug therapy*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone